MARKET

BJDX

BJDX

Bluejay Diagnostics Inc
NASDAQ
0.8028
-0.0012
-0.15%
After Hours: 0.7651 -0.0377 -4.70% 18:24 03/28 EDT
OPEN
0.7890
PREV CLOSE
0.8040
HIGH
0.8098
LOW
0.7820
VOLUME
15.38K
TURNOVER
0
52 WEEK HIGH
13.98
52 WEEK LOW
0.7300
MARKET CAP
1.43M
P/E (TTM)
-0.0829
1D
5D
1M
3M
1Y
5Y
Bluejay Diagnostics Q4 EPS $(1.78) Misses $(0.68) Estimate
Benzinga · 55m ago
BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023
Bluejay Diagnostics reported earnings per share of -$1.78 for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -68 cents. Bluejay Diagnostic just reported results.
Investorplace · 1h ago
Weekly Report: what happened at BJDX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at BJDX last week (0311-0315)?
Weekly Report · 03/18 12:01
Weekly Report: what happened at BJDX last week (0304-0308)?
Weekly Report · 03/11 11:57
Weekly Report: what happened at BJDX last week (0226-0301)?
Weekly Report · 03/04 12:00
Weekly Report: what happened at BJDX last week (0219-0223)?
Weekly Report · 02/26 12:18
12 Health Care Stocks Moving In Friday's After-Market Session
Ocean Biomedical (NASDAQ:OCEA) stock rose 37.6% to $2.16 during Friday's after-market session. The company's market cap stands at $73.6 million. NeuBase Therapeutics and Virax Biolabs Group also moved upwards. Losers include Telesis Bio and Celularity.
Benzinga · 02/23 21:31
More
About BJDX
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a near-patient testing system for triage and monitoring of disease progression. The Company's Symphony platform is a technology platform that provides measurements of key diagnostic biomarkers found in whole blood. The Symphony analyzer orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The Company's first product candidate, an IL-6 test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices (IVDs) market, including sepsis, cardio-metabolic diseases, cancer, and other diseases that require rapid tests.

Webull offers Bluejay Diagnostics Inc stock information, including NASDAQ: BJDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BJDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BJDX stock methods without spending real money on the virtual paper trading platform.